


Obr. 4. Příčiny a intervence nedostatočně kontrolované bronchiální astmy, upravené podle GINA 2024 (3)

Záver

Perzistujúca obštrukcia v dýchacích cestách a vysoká variabilita pľúcnych funkcií s narastaním symptomatiky astmy a jej exacerbáciami sú predikčné faktory pre indikáciu ITT, ktorá redukuje exacerbácie a zlepšuje pľúcne funkcie. Inhalačná triple terapia dokáže zlepšiť kvalitu života astmatikov. Touto liečbou možno predísť

nežiaducim návštevám na urgentných príjmach a hospitalizáciám, či už pre stabilizáciu samotnej bronchiálnej astmy alebo riziko zhoršenia hlavne kardiovaskulárnych komorbidít pri nedostatočnej kontrole astmy. Inhalačná triple terapia v liečbe astmy by si pre uvedené dôvody mala nájsť svoje miesto v pneumologickej aj alergologickej praxi.

PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Práce je původní a nebyla publikována ani není zaslána k recenznímu řízení do jiného média. **Střet zájmů:** Žádný. **Financování:** Ne. **Poděkování:** N/A. **Registrace v databázích:** N/A. **Projednáni etikou komisí:** N/A.

LITERATÚRA

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2017. Available from: <https://ginasthma.org/wp-content/uploads/2019/01/2017-GINA.pdf>.
2. Bagnasco D, Ansotegui I, Baiardina I, et al. Triple inhaled therapy in asthma: Beliefs, behaviours and doubts. *Pulm Pharmacol Therap.* 2024;87:102333. doi: 10.1016/j.pupt.2024.102333. Epub 2024 Nov 19.
3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2024. Available from: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_VMS.pdf.
4. Rodrigo GJ, Rodrigo C. Triple Inhaled Drug Protocol for the Treatment of Acute Severe Asthma*. *CHEST.* 2003;123(6):1908-15.
5. Aalbers R, Park HS. Positioning of long-acting muscarinic antagonists in the management of asthma. *Allergy Asthma Immunol Res.* 2017;9(5):386-393
6. Gosens R, Gross N. Gosens R, Gross N. The mode of action of anticholinergics in asthma. *Eur Respir J.* 2018;52:1701247.
7. Quirce S, Dominguez-Ortega J, Barranco P. Anticholinergics for treatment of asthma. *J Investig Allergol Clin Immunol.* 2015;25:84-93.
8. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. *Clin Rev Allergy Immunol.* 2006;31:181-196.
9. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. *N Engl J Med.* 2012;367:1198-1207.
10. Luz MI, Aguiar R, Morais-Almeida M. The reality of LAMAs for adult asthmatic patients. *Expert Rev Respir Med, Expert Rev Respir Med.* 2020 Nov;14(11):1087-1094. doi: 10.1080/17476348.2020.1794828. Epub 2020 Jul.
11. Calzetta A, Coppola B, et al. The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. *International Journal of Chronic Obstructive Pulmonary Disease.* 2021;16:257-279.
12. Wechsler ME, Oppenheimer JJ. Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β_2 -agonist) in asthma patients: a narrative review. *Journal of asthma.* 2023;60(9):1633-1645.
13. Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate oncedaily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON) [published correction appears in *Respir Med.* 2020 Dec;175:106186]. *Respir Med.* 2020;170:106021.
14. Lazarus SC, Krishnan JA, King TS, et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. *N Engl J Med.* 2019;380(21):2009-2019.
15. Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. *Eur Respir J.* 2007;30(4):653-661.
16. Cazzola M, Puxeddu E, Matera MG, Rogliani P. A potential role of triple therapy for asthma patients. *Expert Rev Respir Med.* 2019;13(11):1079-1085.
17. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), M.M. Cloutier, A.P. Baptist, K. V. Blake, E.G. Brooks, T. Bryant-Stephens, E. DiMango, A.E. Dixon, K.S. Elward, T. Hartert, J.A. Krishnan, R.F. Lemanske Jr., D.R. Ouellette, W.D. Pace, M. Schatz, N.S. Skolnik, J.W. Stout, S.J. Teach, C.A. Umscheid, C.G. Walsh, 2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention Program coordinating committee expert panel working group, *J. Allergy Clin. Immunol.* 2020;146(6):1217-1270.
18. Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. *Lancet Respir Med.* 2021;9(1):69-84. -1.Epub 2020 Sep 9. Erratum in: *Lancet Respir Med.* 2021 Jan 4: PMID: 32918892
19. Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. *Respir Med.* 2016;117:198-206.
20. Paggiaro P, Halpin DM, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. *J Allergy Clin Immunol Pract.* 2016;4:104-113.e2.

Další literatura u autorky
a na www.casopisvnitrnilekarstvi.cz